2022 TREAT-NMD Conference

7 – 9 December 2022

The TREAT-NMD Alliance are organising our 7th international conference focussing on translational medicine in inherited neuromuscular diseases to be held from 7th-9th December 2022 in Vancouver in Canada.
The aim of this international conference will be to share progress and lessons learned in the area of translational medicine in inherited neuromuscular diseases and plan for the delivery of future therapies to patients.
The conference will attract over 300 delegates including academics, patients and carers, patient advocacy organisations and clinical specialists.
TREAT-NMD would like to thank our individual members who shared their thoughts and ideas on the organisation of the 2022 conference.

Day 1 – 8th December 2022

SESSION ONE: Patient engagement

SESSION TWO: Patient engagement and clinical trial considerations in ultra-rare patient groups

SESSION THREE: Global Neuromuscular Care and Trial Considerations

7pm Networking event

7.45pm Keynote speaker: Geralyn Miller, AI for good Research Lab


Day 2 – 9th December 2022

SESSION FOUR: COVID impact on Outcomes, Care & Clinical Trial Design

SESSION FIVE: Living with NMD: practical considerations and QOL

SESSION SIX: Emerging Therapeutics options in NMD

SESSION SEVEN: Future of clinical trial Design

The full conference programme will be available soon.

The website provides information on the conference location, the agenda, opportunities for sponsorship and much more.


Vancouver Convention Centre
1055 Canada Pl,
British Columbia
V6C 0C3,

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern